United States Securities and Exchange Commission

Litigation Release No. 17596 / July 2, 2002

SEC v. Jay S. Laveson, Civ. Action No.02 CV 11336 GAO (D. Mass., filed July
2, 2002)

SEC Charges Jay S. Laveson, a Former Employee of IDX Systems, Inc. with
Insider Trading in Three Stocks

   The Securities and Exchange Commission today announced the filing of a
   civil injunctive action against Jay S. Laveson for illegal insider
   trading in the securities of IDX Systems, Inc., Daou Systems, Inc.,
   and Medical Manager Corporation. The complaint alleges that Laveson, a
   resident of Atkinson, New Hampshire and a former senior financial
   analyst at IDX, made an illegal profit of $128,524 when he traded
   while in possession of material nonpublic information about the three
   companies. Laveson obtained this information during the course of his
   employment at IDX. Laveson agreed to settle this matter by consenting,
   without admitting or denying the allegations, to the entry of a
   judgment enjoining him from future violations of the antifraud
   provisions of the federal securities laws, and ordering him to
   disgorge the sum of $128,524. A civil penalty was not imposed and
   pre-judgment interest was waived based on Laveson's demonstrated
   inability to pay.

   The Commission's complaint alleges that from March 2 through March 4,
   1999, Laveson, while employed at IDX's South Burlington, Vermont
   headquarters, sold and shorted IDX stock. At the time of his IDX
   trades, Laveson was in possession of material nonpublic information
   that IDX's earnings for the quarter ended March 31, 1999, would be
   lower than expected. IDX publicly announced the negative earnings news
   in a press release on March 5, 1999. The complaint further alleges
   that between September 1998 and February 1999, Laveson traded in the
   securities of Daou and Medical Manager while in possession of
   nonpublic information concerning IDX's merger negotiations with both
   companies. Laveson came into possession of the merger information
   while performing work as a member of the IDX due diligence teams that
   reviewed the potential transactions with Daou and Medical Manager. The
   complaint also alleges that on February 5, 1999, Laveson shorted
   Daou's stock, in anticipation of a decline in its price, after
   learning from Daou's chief operating officer that the company expected
   to have a revenue shortfall for the quarter ended December 31, 1998.

   The Commission's complaint alleges that by engaging in insider
   trading, Laveson violated the antifraud provisions of the federal
   securities laws, including Section 17(a) of the Securities Act of 1933
   and Section 10(b) of the Securities Exchange Act of 1934 and Rule